Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 4
1997 1
1998 1
1999 1
2000 2
2001 1
2003 1
2004 1
2005 8
2006 3
2007 5
2008 10
2009 7
2010 9
2011 12
2012 8
2013 8
2014 9
2015 6
2016 11
2017 15
2018 11
2019 11
2020 9
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

144 results
Results by year
Filters applied: . Clear all
Page 1
The intricate role of CXCR4 in cancer.
Chatterjee S, Behnam Azad B, Nimmagadda S. Chatterjee S, et al. Among authors: nimmagadda s. Adv Cancer Res. 2014;124:31-82. doi: 10.1016/B978-0-12-411638-2.00002-1. Adv Cancer Res. 2014. PMID: 25287686 Free PMC article. Review.
Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, Nimmagadda S, Sudini K, Brimacombe KR, Gajghate S, Ma J, Wang A, Xu X, Shahane SA, Xia M, Woo J, Mensah GA, Wang Z, Ferrer M, Gabrielson E, Li Z, Rastinejad F, Shen M, Boxer MB, Biswal S. Singh A, et al. Among authors: nimmagadda s. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. doi: 10.1021/acschembio.6b00651. Epub 2016 Oct 17. ACS Chem Biol. 2016. PMID: 27552339 Free PMC article.
Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Kumar D, et al. Among authors: nimmagadda s. J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7. J Clin Invest. 2019. PMID: 30457978 Free PMC article.
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Venkateswara Rao K, Mease R, Dannals RF, Pomper MG, Nimmagadda S. De Silva RA, et al. Among authors: nimmagadda s. Mol Pharm. 2018 Sep 4;15(9):3946-3952. doi: 10.1021/acs.molpharmaceut.8b00399. Epub 2018 Aug 10. Mol Pharm. 2018. PMID: 30037229 Free PMC article.
PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Lesniak WG, Chatterjee S, Gabrielson M, Lisok A, Wharram B, Pomper MG, Nimmagadda S. Lesniak WG, et al. Among authors: nimmagadda s. Bioconjug Chem. 2016 Sep 21;27(9):2103-10. doi: 10.1021/acs.bioconjchem.6b00348. Epub 2016 Aug 9. Bioconjug Chem. 2016. PMID: 27458027 Free PMC article.
Ovarian Cancer Targeted Theranostics.
Nimmagadda S, Penet MF. Nimmagadda S, et al. Front Oncol. 2020 Jan 21;9:1537. doi: 10.3389/fonc.2019.01537. eCollection 2019. Front Oncol. 2020. PMID: 32039018 Free PMC article. Review.
Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S. Chatterjee S, et al. Among authors: nimmagadda s. Biochem Biophys Res Commun. 2017 Jan 29;483(1):258-263. doi: 10.1016/j.bbrc.2016.12.156. Epub 2016 Dec 24. Biochem Biophys Res Commun. 2017. PMID: 28025143 Free PMC article.
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.
Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, Makarev E, V Artemov A, Wysocki PT, Mehra R, Nimmagadda S, Marchionni L, Sidransky D, Borrello IM, Izumchenko E, Bedi A. Ravi R, et al. Among authors: nimmagadda s. Nat Commun. 2018 Feb 21;9(1):741. doi: 10.1038/s41467-017-02696-6. Nat Commun. 2018. PMID: 29467463 Free PMC article.
144 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page